3CL protease is an ideal target for the research and development of anti-new coronavirus drugs. In this paper, the patent application situation of 3CL protease inhibitors in the field of anti-SARS-CoV-2 was analyzed. The focuses were put on the application time distribution, profile of patent applicants, and status of key products related to 3CL protease inhibitors, to reflect the global patent application trend, reveal the patent barriers faced by our country in the research and development of the drug, and provide support for the drug research and development. Combined with the results of patent analysis, this paper suggested that Chinese applicants expand their research and development ideas based on traditional Chinese medicine resources, and at the same time pay attention to the layout of overseas patents, and accelerate the in-depth integration of production, education, and research.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |